达罗他胺维持治疗用于转移性去势抵抗性前列腺癌紫杉烷治疗后疾病无进展患者(SAKK 08/16)
SAKK 08/16 是一项随机II期研究,92例既往接受过雄激素受体通路抑制剂(ARPI)且紫杉烷治疗后疾病无进展的转移性去势抵抗性前列腺癌(mCRPC)患者随机接受达罗他胺600mg每日两次或安慰剂每日两次。12周影像学无进展生存率(rPFS)达罗他胺组64.7% vs 安慰剂组52.2%(P=.127),中位rPFS 5.5 vs 4.5个月(HR 0.54,95%CI 0.32-0.91;P=.017),中位无事件生存5.4 vs 2.9个月(HR 0.46,95%CI 0.29-0.73;P=.001),PSA 50%缓解率22% vs 4%(P=.014),中位OS 24 vs 21.3个月(HR 0.62,95%CI 0.3-1.26;P=.181),治疗相关不良事件两组相似。
要点
- 达罗他胺维持治疗较安慰剂显著延长中位rPFS(5.5 vs 4.5个月,HR 0.54)和中位无事件生存(5.4 vs 2.9个月,HR 0.46)。
- 12周rPFS率64.7% vs 52.2%(P=.127),未达统计学显著。
- PSA 50%缓解率22% vs 4%(P=.014),中位OS 24 vs 21.3个月(HR 0.62,P=.181),治疗相关不良事件两组相似。
核心结论
- SAKK 08/16达到主要终点,显示既往紫杉烷化疗和至少一种ARPI后换用达罗他胺维持治疗带来统计学显著但临床获益有限的rPFS延长,且耐受性良好。
- 达罗他胺维持治疗的中位OS似乎有希望。
- 若这些发现能在大规模试验中得以证实,维持治疗可能成为mCRPC管理的新策略,尤其是对既往ARPI应答良好的患者。
研究设计与样本
- 瑞士临床癌症研究组(SAKK)08/16是一项随机II期研究。
- 纳入既往接受过ARPI、随后紫杉烷治疗后疾病无进展的mCRPC患者,随机分配至达罗他胺600mg每日两次或安慰剂每日两次。
- 共26个中心入组92例患者。
- 主要终点为12周时影像学无进展生存(rPFS);次要终点包括rPFS、无事件生存、总生存(OS)、前列腺特异性抗原(PSA)50%缓解率和不良事件。
主要发现
- 既往紫杉烷为多西他赛者占93%,卡巴他赛者占7%。
- 既往ARPI为阿比特龙者占60%,恩扎卢胺者占31%,两者均用者占9%。
- 12周rPFS率达罗他胺组64.7% vs 安慰剂组52.2%(P=.127)。
- 中位rPFS达罗他胺组5.5个月 vs 安慰剂组4.5个月(HR 0.54,95%CI 0.32-0.91;P=.017),中位无事件生存达罗他胺组5.4个月 vs 安慰剂组2.9个月(HR 0.46,95%CI 0.29-0.73;P=.001)。
- PSA 50%缓解率达罗他胺组22% vs 安慰剂组4%(P=.014);中位OS达罗他胺组24个月 vs 安慰剂组21.3个月(HR 0.62,95%CI 0.3-1.26;P=.181);治疗相关不良事件两组相似。
临床怎么用
- 作者认为,若这些发现能在大规模试验中得以证实,维持治疗可能成为mCRPC管理的新策略,尤其是对既往ARPI应答良好的患者。
局限性
- 原文在结论中写明若这些发现需在更大规模试验中证实。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To assess the efficacy and safety of darolutamide maintenance after successful taxane chemotherapy in patients with metastatic castration-resistant prostate cancer (mCRPC). PATIENTS AND METHODS: Swiss Group for Clinical Cancer Research (SAKK) 08/16 is a randomized phase II study. Patients with mCRPC who received prior androgen-receptor pathway inhibitors (ARPIs) and subsequently had nonprogressive disease on a taxane were randomly assigned to darolutamide 600 mg twice a day or placebo twice a day. The primary end point was radiographic progression-free survival (rPFS) at 12 weeks. Secondary end points were rPFS, event-free survival, overall survival (OS), prostate-specific antigen (PSA) 50% response rate, and adverse events. RESULTS: Overall, 92 patients were recruited by 26 centers. Prior taxane was docetaxel in 93% and cabazitaxel in 7%. Prior ARPI was abiraterone in 60%, enzalutamide in 31%, and both in 9%. rPFS at 12 weeks was significantly improved with darolutamide (64.7% v 52.2%; P = .127). Median rPFS on darolutamide was 5.5 versus 4.5 months on placebo (hazard ratio [HR], 0.54 [95% CI, 0.32 to 0.91]; P = .017), and median event-free survival was 5.4 versus 2.9 months (HR, 0.46 [95% CI, 0.29 to 0.73]; P = .001). PSA 50% response rate was improved (22% v 4%; P = .014). Median OS for darolutamide was 24 versus 21.3 months for placebo (HR, 0.62 [95% CI, 0.3 to 1.26]; P = .181). Treatment-related adverse events were similar in both arms. CONCLUSION: SAKK 08/16 met its primary end point, showing that switch maintenance with darolutamide after prior taxane chemotherapy and at least one ARPI resulted in a statistically significant but clinically modest rPFS prolongation with good tolerability. The median OS with darolutamide maintenance appears promising. Should these findings be confirmed in a larger trial, maintenance treatment could be a novel strategy in managing patients with mCRPC, especially those who responded well to prior ARPI.
引用
- Gillessen S, Procopio G, Hayoz S, et al. Darolutamide Maintenance in Patients With Metastatic Castration-Resistant Prostate Cancer With Nonprogressive Disease After Taxane Treatment (SAKK 08/16). J Clin Oncol. 2023. PMID: 36753698. doi:10.1200/JCO.22.01726
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。